|
J Biol Chem, Vol. 273, Issue 43, 28444-28453, October 23, 1998
The DSD-1 Carbohydrate Epitope Depends on Sulfation, Correlates
with Chondroitin Sulfate D Motifs, and Is Sufficient to Promote
Neurite Outgrowth*
Albrecht M.
Clement ,
Satomi
Nadanaka§,
Kimiko
Masayama§,
Claudia
Mandl ,
Kazuyuki
Sugahara§, and
Andreas
Faissner ¶
From the Department of Neurobiology, University of
Heidelberg, Im Neuenheimer Feld 364, D-69120 Heidelberg, Germany, the
§ Department of Biochemistry, Kobe Pharmaceutical
University, Higashinada-ku 20, Kobe 658-8558, Japan, and
¶ Laboratoire de Neurobiologie du Développment et
de la Régéneration, UPR 1352, Centre de Neurochimie du CNRS
et Université Louis Pasteur, F-67084 Strasbourg, France
 |
ABSTRACT |
The neural chondroitin sulfate (CS) proteoglycan
(PG) DSD-1-PG was originally identified with the monoclonal antibody
(mAb) 473HD. It promotes neurite outgrowth of hippocampal neurons when coated as a substrate in the presence of polycations. This effect is
inhibited by mAb 473HD that specifically recognizes the DSD-1 epitope.
The DSD-1 epitope is also detectable in CS-C and CS-D preparations from
shark cartilage but not in other chondroitin sulfates that are
structurally related and differ in their sulfation patterns.
Non-sulfated DSD-1-PG and chemically desulfated CS-D were not
recognized by mAb 473HD, suggesting that the DSD-1 epitope depends on
sulfation. It was possible to enrich DSD-1 epitope-bearing carbohydrates and D disaccharide units from CS-C and CS-D preparations on a mAb 473HD affinity matrix. This indicates that the DSD-1 epitope
represents a distinct glycosaminoglycan structure containing D units.
The analysis of glycosaminoglycan digestion products by high pressure
liquid chromatography revealed that DSD-1-PG preparations contain a
unique D disaccharide unit as well as an A, a C, and a non-sulfated
disaccharide unit. In neurite outgrowth assays with hippocampal
neurons, substrate-bound CS-D promoted neurite outgrowth, whereas CS-A,
CS-B, or CS-C did not. This effect of CS-D was inhibited by mAb 473HD.
DSD-1 epitope-enriched fractions obtained from CS-D and CS-C promoted
neurite outgrowth, whereas CS-C had no such effect prior to enrichment
on the mAb 473HD matrix. Based on these findings we conclude that the
DSD-1 epitope by itself is sufficient to promote neurite outgrowth and
that this activity is possibly associated with D motifs.
 |
INTRODUCTION |
During development of the nervous system, molecules of the
extracellular matrix (ECM)1
(1) play an important regulatory role in processes such as cell
migration, cell differentiation, neurite outgrowth, and the establishment of synaptic connections (for review see Refs. 1 and 2).
ECM molecules interact with various components, e.g. growth
factors or other constituents of the ECM, which are thus concentrated
in topographically restricted territories and arranged in pericellular
superstructures (3, 4). Several types of receptors have been described
to mediate cell-surface interactions with the ECM, most notably the
integrins, heterodimeric transmembrane proteins, and some proteoglycans
(2, 5). Considering the biochemical subclasses, much more is known
about structure and functions of the well characterized ECM
glycoproteins laminin, fibronectin, and tenascin-C (6-8) than about
the functions of proteoglycans (PGs) during neural development and
regeneration.
PGs constitute a heterogeneous class of molecules, which comprise a
protein core and at least one covalently linked sulfated glycosaminoglycan (GAG) chain (9). Each GAG chain consists of repeating
disaccharide units, and the composition of these dimers and their
sulfation patterns determine distinct GAG types. The resulting
structural diversity is reflected in the different functions, which
have been attributed to PGs during development and regeneration (for
review see Refs. 1, 10, and 11). Chondroitin sulfate PGs like neurocan
and phosphacan (12, 13) are reported to have primarily inhibitory
properties in cell adhesion and neurite outgrowth, and some of these
effects are thought to be mediated through the core protein (14-16).
Yet, the core protein of an as yet unidentified PG (17) and the
integral DSD-1-PG have been shown to promote neurite outgrowth (18) and
the latter to be expressed in areas of axonal growth (19). Several
lines of investigations suggest, however, that not only the core
proteins but also the GAGs are involved in neural development. Thus, it has been reported that digestion of chondroitin sulfate by injection of
chondroitinase ABC in vivo modifies the patterning and
differentiation of retinal ganglion cells and their axonal projections
during chick retina development (20). Along those lines, other studies suggest an influence of soluble GAGs on the establishment of neuronal polarity (21, 22), the promotion of neuronal survival (23), and the
attachment of dopaminergic neurons in wounded adult striatum (24). The
role of chondroitin sulfate in neurite outgrowth is controversial. An
inhibitory influence of chondroitin sulfates on neurite outgrowth
(25-29) is consistent with studies showing an enrichment of
chondroitin sulfate in glial boundaries supposed to restrain neurite
growth (30, 31) and in lesions of the central nervous system (32-36).
In contrast to those findings, other studies have described either no
or a stimulatory influence of chondroitin sulfate on neurite outgrowth
(18, 22, 37, 38). These results are in agreement with the findings that
chondroitin sulfates are up-regulated after lesion during the period of
sciatic nerve regeneration (39, 40) and required for the regeneration of retinal goldfish axons (41). The divergence of results might have
been caused by differences of the presentation of chondroitin sulfate
and/or chondroitin sulfate PGs and by the use of distinct neuronal cell
types. Additionally, chondroitin sulfates bear a considerable
structural variability, which is presently not well understood. The
basic disaccharide, which consists of glucuronic acid and
N-acetylgalactosamine, can be modified by ester sulfation reactions at various positions. The chemical heterogeneity and the
formation of defined structured motifs on singular chondroitin sulfate
chains have been documented by several detailed studies (38, 42, 43).
In addition, studies with monoclonal antibodies (mAbs) directed against
specific epitopes on chondroitin sulfate chains revealed restricted
spatio-temporal patterns of expression in various tissues (44-46). The
regulation of chondroitin sulfate isoforms, which vary both in the
degree and the positions of sulfation, is compatible with the
mediation of distinct functions during development (46).
One of these structures is the DSD-1 epitope, a chondroitin sulfate
modification, which has been identified on the glial-derived DSD-1-PG
using the specific mAb 473HD. The corresponding epitope could be
detected in chondroitin sulfate C (CS-C) and CS-D preparations from
shark cartilage but not in those of the other members of the
chondroitin sulfate family (18, 38). Substrate-bound DSD-1-PG promotes
neurite outgrowth of several neuronal types including hippocampal
neurons. Perturbation studies using mAb 473HD or chondroitinase ABC
indicated that this functional activity requires the presence of the
DSD-1 epitope, suggesting that this epitope represents a functional GAG
structure (18).
To explore this concept, the structure-function relationship of the
DSD-1 epitope, which is predominantly expressed in the nervous system,
was investigated. We show here that chondroitin sulfate fractions
containing the DSD-1 epitope promote neurite outgrowth of embryonic day
18 (E18) hippocampal neurons. This effect is directly correlated with
the amount of substrate bound DSD-1 epitope-containing GAGs.
Furthermore, recognition of the the DSD-1 epitope by mAb 473HD and the
neurite outgrowth promotion by CS-D are dependent on the sulfation of
the GAGs. This opens the possibility that sulfation patterns regulate
the functional potential of chondroitin sulfates.
 |
EXPERIMENTAL PROCEDURES |
Animals--
For preparation of rat embryonic day 18 (E18)
hippocampal neurons or mixed postnatal mouse cerebellar cultures, SD
rats or NMRI mice were used, respectively. The animals were kept at the local facility (animal house of the University of Heidelberg, Zentralbereich Theoretikum, Heidelberg, Germany).
Materials--
Chondroitin sulfates preparations from the
folowing biological sources were purchased from Seikagaku Corp. (Tokyo,
Japan) or from Sigma (Deisenhofen, Germany): CS-A, bovine trachea;
CS-B, bovine mucosa; CS-C and CS-D, shark cartilage; CS-E, squid
cartilage. Proteinase-free preparations of chondroitinase ABC were
obtained from Boehringer Mannheim (Mannheim, Germany). Other chemicals, including cell culture media, were purchased from Sigma, Merck (Darmstadt, Germany), Life Technologies, Inc. (Eggenstein, Germany), or
Boehringer Ingelheim Bioproducts (Heidelberg, Germany) unless specified
otherwise.
Monoclonal antibody (mAb) 473HD, a rat IgM antibody directed against
the DSD-1 epitope, and polyclonal rabbit IgG pDSD-1-PG antibodies
(polyclonal antibody) were prepared as described previously (18); mAb
anti-tubulin (clone DM 1A) was purchased from Sigma; the secondary
antibodies derivatized with fluorescein or horseradish peroxidase
against rat IgM or rabbit IgG were obtained from Dianova (Hamburg,
Germany). Protein A-Sepharose was purchased from Pharmacia (Freiburg,
Germany).
Cell Culture and Immunocytochemistry--
Rat hippocampal neuron
cultures were established from E18 animals as described by Goslin and
Banker (47), with some modifications (48). Cells were plated on glass
coverslips at low density (8,000-10,000 cells/cm2) and
cultivated in minimal Eagle's medium (MEM) supplemented with the N2
mixture, namely 5 mg/ml insulin, 20 nM progesterone, 100 µM putrescine, and 30 nM selenite (49), and
0.1 mM pyruvate, 0.1% (w/v) ovalbumin, and 0.01% (w/v)
apo-transferrin. The cultures were kept in a humidified atmosphere with
5% CO2 at 36 °C.
Glass coverslips were precoated with 15 µg/ml
poly-DL-ornithine in 0.1 M borate buffer, pH
8.1, for 1 h, washed three times with double distilled
H2O, and coated with 50 µl of 16 µg/ml chondroitin sulfates (total weight or 5 µg/ml as glucuronic acid equivalents (GlcUA)) in PBS overnight at 37 °C. Thereafter, the coverslips were
washed three times with PBS and flooded with N2 medium. For antibody
blocking experiments, mAb 473HD was added to the medium at a final
concentration of 10 µg/ml for 1.5 h before plating the cells.
The cultures were fixed, permeabilized, and stained with a tubulin
monoclonal antibody as described (38).
Mixed cerebellar cultures were prepared as described elsewhere (50).
These and cultures of the oligodendroglial-derived cell line Oli-neu
(51) were fixed with 4% paraformaldehyde for 20 min at RT, blocked
with 1% (w/v) bovine serum albumin (BSA) in PBS for at least 30 min at
RT, and stained with mAb 473HD and pDSD-1-PG for 30 min at RT. The
bound antibodies were detected with fluorescein-conjugated goat
anti-rat IgM and goat anti-rabbit IgG, respectively (both 1:70 to 1:100
in blocking buffer).
Morphometric Analysis and Statistics--
The stained
hippocampal neurons were analyzed with a morphometric station (Leica,
Bensheim, Germany; invert microscope, camera, Quantimed 500 MC). The
length of the longest neurite was determined by drawing this process in
the interactive mode of the program. Only cells with neurites longer
than one neuronal cell body diameter were counted as neurite-bearing
cells. The fractions of process forming neurons and the distribution of
the longest neurites obtained under different experimental conditions
were compared using the non-parametric Mann-Whitney U test
in the SigmaStat program (SPSS Inc., Chicago).
Enzyme-linked Immunosorbent Assay (ELISA)--
Purified DSD-1-PG
was absorbed overnight on polyvinylpyrrolidone (Falcon) at 0.5 µg/ml
as GlcUA in 0.1 M NaHCO3, pH 8.1, 100 µl/well. The wells were washed three times with PBS and blocked with
1% (w/v) BSA in PBS including 0.05% (v/v) Tween 20 (PBST) for 1 h at RT. Subsequently, the polyvinylpyrrolidone plates were incubated
with mAb 473HD (1-5 µg/ml final concentration) in blocking reagent
for 1 h at RT. For competition studies, mAb 473HD was preincubated
with different GAGs for 2 h at 37 °C at various concentrations (see "Results") and added to the DSD-1-PG in the presence of
soluble competitors. The plates were washed three times with PBST and incubated for 1 h at RT with specific anti-rat IgM secondary
antibodies derivatized with horseradish peroxidase diluted 1:5,000 in
blocking buffer. After three washes, the plates were developed with
ABTS (52). The colored reaction product was quantified with an ELISA reader (Titertek multiscan; Flow Laboratories, Meckenheim, Germany) at
OD405 nm. Experiments were performed in triplicate. The percent inhibition was calculated as follows: % inhibition = ((ODtest ODcontrol)/Odcontrol) × 100.
Biosynthetic Labeling of Cell Cultures and
Immunoprecipitation--
For biosynthetic labeling of proteins or
carbohydrates with [35S]methionine/cysteine (250 µCi/ml) or Na235SO4 (300 µCi/ml) (Amersham Buchler GmbH, Braunschweig, Germany), postnatal
cerebellar cultures or Oli-neu cells were cultured in Na2SO4-free and methionine/cysteine-free
Dulbecco's modified Eagle's medium for 45 min. Thereafter, 7 mM sodium chlorate was added to the medium, and after a
further 15 min either [35S]methionine/cysteine (250 µCi/ml) together with unlabeled Na2SO4 (10 µg/ml) or Na235SO4 (300 µCi/ml)
together with unlabeled methionine and cysteine (each 30 µg/ml) was
added to the cultures for 4 h. Subsequently, the supernatants were
collected, and a mixture of proteinase inhibitors was added
(benzamidine and phenylmethylsulfonyl fluoride at 1 mM;
aprotinin, iodoacetamide, and pepstatin at 1 µg/ml). The cells were
lysed for 20 min on ice in 0.15 M NaCl, 20 mM
Tris-HCl, 1 mM EDTA, 1 mM EGTA, 1% (v/v)
Triton X-100, 1% BSA (w/v), pH 7.4, with added proteinase inhibitors.
Supernatants and detergent extracts were cleared by consecutive rounds
of centrifugation at 800 × g, 4 °C for 10 min and
at 100,000 × g, 4 °C for 45 min. The
immunoprecipitation was carried out as described (53). In brief, 1 ml
of the cleared lysates or cell culture supernatants were mixed with 20 µg/ml mAb 473HD or 200 µg/ml pDSD-1-PG for at least 1 h or
overnight at 4 °C. With the polyclonal antibody the aliquots were
incubated for 1 h at 4 °C with 150 µl of preswollen protein
A-Sepharose conjugate, whereas with the mAb 473HD aliquots were
incubated with 150 µl of protein A-Sepharose preincubated with goat
anti-rat IgM antibodies for 1 h at 4 °C (20 µg/ml final
concentration). After several washes the Sepharose beads were
resuspended in 100 µl of chondroitinase ABC digestion buffer (40 mM sodium acetate, 0.1% (w/v) BSA, pH 8.0, with protease
inhibitors). Half of the material was supplemented with the same volume
of 2-fold concentrated SDS sample buffer and separated on a 4-10%
gradient SDS-polyacrylamide gel. The radioactive signals were monitored
on an x-ray sensitive film (Amersham Buchler GmbH, Braunschweig) and
developed with a Kodak x-ray developing machine (Kodak M35 X-Omat
processor) or detected on a phosphorimager plate (Fuji, MacBas 100;
RayTest, Straubenhardt, Germany).
Preparation of Tissue Extracts--
Different tissues of adult
NMRI mice were homogenized in 50 mM Tris-HCl, 50 mM sodium acetate, 60 mM octyl glucoside, pH
8.0, supplemented with a mixture of proteinase inhibitors (soybean trypsin inhibitor, antipain, aprotinin at 10 µM;
phenylmethylsulfonyl fluoride at 5 µM; pepstatin and
leupeptin at 2 µM). The homogenate was extracted for
1 h at 4 °C with gentle stirring and cleared by centrifugation
at 100,000 × g, 4 °C for 1 h. The protein
content of the extract was determined with the Bio-Rad protein assay
using BSA as a standard (Bio-Rad, München, Germany). For Western
blot analysis 100 µg of protein were loaded per lane.
SDS-PAGE and Western Blots--
SDS-PAGE was performed on
4-10% gradient gels (54). Proteins were transferred according to
standard protocols (55) on a nylon membrane (polyvinylidene difluoride;
Millipore, Eschborn, Germany). Membranes were blocked with 4% (w/v)
milk powder in PBST for 30 min at RT. MAb 473HD (1-3 µg/ml final
concentration) diluted in blocking buffer was incubated for 1 h at
RT. To detect the bound antibodies the membranes were incubated with
horseradish peroxidase-conjugated goat anti-rat IgM diluted in blocking
buffer for 1 h at RT. After washing (five times for 7 min with
PBST), bound antibodies were visualized by enhanced chemiluminescence (ECL Kit, Amersham-Buchler).
Determination of Uronic Acid Equivalents--
Glucuronic acid
(GlcUA) concentrations were determined with a colorimetric assay using
m-hydroxydiphenyl (56) or carbazole (57). CS-C or GlcUA were
used as standards.
Desulfation of CS-D--
CS-D was desulfated as described (58)
by treating the pyridinium salt of the polysaccharide with 90% (v/v)
dimethyl sulfoxide for 1, 2.5, and 5 h at 80 °C. The fractions
were analyzed by HPLC. The efficiency of the reaction is shown in Table
II.
Radioabeling of Chondroitin Sulfates--
The radiolabeling of
chondroitin sulfate chains was conducted by 3H-acetylation
of N-deacetylated galactosamine residues by treating CS-D
polysaccharides successively with hydrazine and then
[3H]acetic anhydride (59). N-Deacetylation was
carried out as described (60). CS-D (1 mg) was mixed with 0.2 ml of
anhydrous hydrazine and 28 mg of hydrazine sulfate. The tube was sealed and heated at 96 °C for 6 h. At the end of the reaction period, the mixture was dessicated. The N-deacetylated chondroitin
sulfate chains were recovered by precipitation with 80% (v/v) ethanol. The resultant precipitate was dissolved in 200 µl of 10% methanol containing 0.05 M Na2CO3. The
solution was kept on ice, and 2.5 mCi of [3H]acetic
anhydride was added. The reaction was agitated, and the pH was kept
between 7.0 and 7.5 by intermittent additions of 10% (v/v) methanol
saturated with Na2CO3. The reaction was
continued for a total period of 1 h, with repeated additions of
2.5 mCi of [3H]acetic anhydride every 20 min. Unlabeled
acetic anhydride was then added to the sample to complete the
acetylation. During a 1-h period, three portions of 1 µl of acetic
anhydride were added, and the pH was maintained neutral as above. After
completion of acetylation, the reaction mixture was applied to a column
(1 × 47 cm) of Sephadex G-50 (fine grade), which was eluted with
0.25 M NH4HCO3 containing 7% (v/v)
propyl alcohol. Labeled chondroitin sulfate chains excluded from the
gel were pooled and dessicated. The hydrazinolysis conditions
corresponded to those used for N-deacetylation but not for
release of N-glycans from core peptides (61). No significant
structural alterations were caused by this treatment, as evidenced by
the observation that complete degradation to the expected disaccharides
could be obtained by chondroitinase ABC digestion.
Immunoaffinity Chromatography--
The following procedures were
performed at 4 °C. 3H-Acetylated CS-D (5 × 105 cpm/260 µg) was applied to a column (3.5-ml bed
volume) of Sepharose 4B, which had been coupled with mAb 473HD and
equilibrated with PBS. The resin contained the antibody at a
concentration of 1.4 mg/ml. The column was washed with PBS. The
absorbed materials were eluted with 0.1 M diethylamine, 0.1 M NaCl, 1 mM EDTA, and 1 mM EGTA,
pH 11.5. One-ml fractions were collected and monitored by scintillation
counting. For inhibition experiments on the mAb 473HD affinity matrix
[3H]CS-D (3000 cpm) was mixed with unlabeled CS-A or CS-D
(50 µg), and the mixture was applied to a column (3.5 ml bed volume)
of 473HD-Sepharose as above. The bound and unbound fractions were quantified by scintillation counting to estimate inhibition of the
binding of the labeled CS-D by unlabeled CS isoforms.
To get DSD-1 epitope-enriched fractions, CS-C was loaded on the
affinity column. Unbound and bound materials were pooled and named
fraction C-FR 1UB and C-FR 1, respectively. They were concentrated, desalted through a column (1.0 × 43 cm) of Sephadex G-50 (fine grade), and lyophilized. Fraction C-FR1 UB was separated into an
unbound (C-FR 2UB) and a bound fraction (C-FR 2) by rechromatography. Likewise, fractions C-FR UB and C-FR 3 were obtained from fraction C-FR
2UB by the third chromatography. The same procedure was done with CS-D
as well. Each fraction was quantified by the carbazole method using
GlcUA as a standard (57).
Analysis of Chondroitin Sulfate Chains Attached to
DSD-1-PG--
DSD-1-PG (50.3 nmol as GlcUA) was digested using 25 milliunits of chondroitinase ABC lyase as described previously (62). The digest corresponding to 8.4 nmol of GlcUA was analyzed by HPLC on
an amine-bound silica PA03 column (4.6 × 250 mm; YMC Co., Kyoto,
Japan) as described (63, 64). HPLC was performed in an LC-10AS system
(Shimadzu Co., Kyoto, Japan) using a linear gradient from 16 to 530 mM NaH2PO4 over a 60-min period at
a flow rate of 1.0 ml/min at RT. Eluates were monitored by UV
absorbance at 232 nm. Identification and quantification of the
resulting disaccharide units were achieved by comparison with
chondroitin sulfate-derived authentic unsaturated disaccharides and by
enzymatic digestion using hexuronate-2-sulfatase, chondro-4- or
6-sulfatases as reported (62).
 |
RESULTS |
The DSD-1 Epitope Is Predominantly Expressed in the Nervous
System--
It has been previously shown that mAb 473HD recognizes an
epitope primarily expressed on the neural chondroitin sulfate
proteoglycan DSD-1-PG, which is produced by immature glial cells (18,
65). To investigate whether the DSD-1 epitope is specifically expressed in the nervous system, a Western blot analysis of adult mouse tissues
was performed (Fig. 1). When equal
amounts of protein were loaded, mAb 473 HD reactivity was only found in
the octyl glucoside extracts of the cerebellum and the residual brain
but not in extracts of several other organs, such as liver, spleen, kidney, thymus, lung, and heart. The data suggest a tissue-related restriction with a predominant expression of the DSD-1 epitope in the
adult mouse brain.

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 1.
Western blot analysis of different mouse
tissue extracts by mAb 473HD. Western blots of detergent extracts
of adult mouse tissues as indicated were performed. mAb 473HD
predominantly recognized the DSD-1-PG expressed in nervous tissue as a
polydisperse smear in the high molecular weight range.
|
|
The DSD-1 Epitope Is Dependent on the Sulfation of CS--
mAb
473HD recognizes an epitope on GAGs of the chondroitin sulfate family
(18). Recently it has been shown that the DSD-1 epitope is localized in
CS-C and CS-D preparations but not in those of CS-A, CS-B, or CS-E
(38). The main difference between these carbohydrates resides in the
sulfation pattern, whereas the common structure is based on
disaccharides composed of glucuronic acid (or the epimer iduronic acid
in case of CS-B) and N-acetylgalactosamine. To test whether
sulfation is critical for the recognition of the DSD-1 epitope by mAb
473HD, the addition of sulfate groups to newly synthesized polymers was
blocked in vitro. To this end Oli-neu cells, a
DSD-1-PG-producing oligodendroglial precursor cell line (51, 65), were
grown in the presence of sodium chlorate, a reagent that suppresses the
addition of sulfate groups to proteins and carbohydrates by up to 95%
(66). Sodium chlorate blocks the ATP-sulfurylase, the first enzyme in
the biogenesis of phosphoadenosine-phosphosulfate, which is the
ubiquitous co-substrate for sulfation. The protein biosynthesis is not
affected by sodium chlorate (Fig.
2A). Immunoprecipitation and
immunocytochemistry of the treated versus the untreated
cells with mAb 473HD showed that the DSD-1 epitope was not present on the cells treated with sodium chlorate. In contrast, the polyclonal antibody pDSD-1-PG still recognized DSD-1-PG, indicating that the core
protein was correctly synthesized by the chlorate-treated Oli-neu cells
(Fig. 2B and Fig. 3).
Analogous results were obtained when the experiment was carried out
with mixed cerebellar cultures, which also synthesize DSD-1-PG
(18).2

View larger version (50K):
[in this window]
[in a new window]
|
Fig. 2.
Immunoprecipitation of DSD-1-PG from Oli-neu
culture supernatants. The expression of the DSD-1-PG in sodium
chlorate-treated Oli-neu cells was studied by
immunoprecipitation with mAb 473HD and the polyclonal serum
pDSD-1-PG. A, shows a fluorograph of a 4-10% SDS gradient
gel with supernatants of Oli-neu cells cultured in the presence of
Na235SO4 or
[35S]methionine/cysteine. Sodium chlorate suppressed the
incorporation of Na235SO4, whereas
the [35S]methionine/cysteine incorporation was not
affected. B, the autoradiograph of a 4-10% SDS gradient
gel resolving immunoprecipitates of
[35S]methionine/cysteine-labeled Oli-neu culture
supernatants shows that the DSD-1-PG was precipitated by mAb 473HD from
cells cultured in the absence but not in the presence of sodium
chlorate. pDSD-1-PG did recognize the DSD-1-PG when expressed by sodium
chlorate-treated and -untreated Oli-neu cells.
|
|

View larger version (107K):
[in this window]
[in a new window]
|
Fig. 3.
Expression of the DSD-1 epitope by sodium
chlorate-treated Oli-neu cells. Oli-neu cells were cultured
without (A, B, E, and F) or
in the presence of sodium chlorate (C, D, G, and
H) and stained with mAb 473HD (A and
C) and pDSD-1-PG (E and G) as
described under "Experimental Procedures." Notably, the staining
for mAb 473HD is less prominent on the chlorate-treated as compared
with the cells cultured in the absence of sodium chlorate. The staining
for pDSD-1-PG is not affected in either condition. Bar, 50 µm.
|
|
Alternatively, sulfate groups from GAG preparations were chemically
removed. The pyridinium salt of CS-D, which contains notable amounts of
the DSD-1 epitope (38), was partially desulfated by dimethyl sulfoxide
for 1 h (DS 1), 2.5 h (DS 2), and 5 h (DS 3). The
desulfation procedure resulted in a reduction of
SO42 groups of 16, 36, and 64%,
respectively, but did not significantly alter the structure of CS-D as
shown by a complete breakdown of CS-D to usual disaccharides upon
chondroitinase ABC treatment (not shown). To test whether desulfation
has an influence on the recognition of the DSD-1 epitope by mAb 473HD,
the fractions were subsequently analyzed in a competition ELISA (Table
II). In this approach the most extensively desulfated fraction (DS 3)
could not inhibit the binding of mAb 473HD to the immobilized DSD-1-PG, whereas intact CS-D efficiently prevents this interaction. It is
noteworthy that fraction DS 2 is as inefficient as DS 3 to block the
interaction of mAb 473HD with the DSD-1-PG. Thus, sulfation is critical
for the synthesis of the DSD-1 epitope and its recognition by mAb
473HD.
DSD-1 Epitope-bearing Carbohydrates Can Be Enriched on a mAb 473HD
Affinity Column--
To enrich for DSD-1 epitope-bearing
carbohydrates, tritiated CS-D ([3H]CS-D) was loaded on a
mAb 473HD affinity column. After washing with loading buffer, a
substantial fraction of the applied activity was retained on the
column. The binding of [3H]CS-D could be blocked by the
addition of unlabeled CS-D (Fig. 4B) but not with unlabeled
CS-A (Fig. 4A), underlining that DSD-1 epitope-bearing
carbohydrates but not other chondroitin sulfates are specifically
enriched by the mAb 473HD affinity matrix. These results support the
previous conclusion that the DSD-1 epitope is contained in CS-D
preparations (38). To examine whether the DSD-1 epitope is comprised in
all carbohydrate polymers of CS-D mixtures either commercially
available CS-C or CS-D were repetitively loaded on the mAb 473HD
affinity column. The eluates of three consecutive chromatography steps
and the final unbound material were analyzed by competition ELISA using
purified neural DSD-1-PG (CS-C affinity retained fraction of the first,
second, and third chromatographies were named C-FR 1, C-FR 2, and
C-FR3, respectively; C-FR UB represents the unbound fraction; likewise
the corresponding fractions with CS-D were named D-FR 1, D-FR 2, D-FR
3, and D-FR UB, respectively) (Fig. 4, C and D).
Carbohydrates of all fractions displayed comparable sizes of at least
10 kDa as shown by size exclusion chromatography during the
purification procedure. The fraction with the highest affinity for mAb
473HD was the eluate of the first round of chromatography (C-FR 1 in
case of CS-C; D-FR 1 in case of CS-D), whereas the unbound
carbohydrates of the third cycle of purification (C-Fr UB; D-FR UB) did
not interfere with the binding of the mAb 473HD to the immobilized
DSD-1-PG. The disaccharide analysis of the DSD-1 epitope-enriched
fractions revealed that the D disaccharide content was highest in the
most enriched fractions (Table I). These
findings reinforce the notion that DSD-1 epitope-bearing GAGs are
specifically enriched on the mAb 473HD affinity column. They also
suggest that the DSD-1 epitope is localized on subpopulations of
carbohydrate polymers contained in CS-C or CS-D preparations and that
the D disaccharide unit contributes to the DSD-1 epitope, although the
sequential arrangement of the disaccharide units has yet to be
determined.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 4.
Enrichment of DSD-1 epitope-bearing
carbohydrates on a mAb 473HD affinity matrix.
[3H]CS-D was loaded on an mAb 473HD affinity column in
the presence of non-labeled CS-A. A, most of the
radioactivity was bound to the column and eluted with pH 11.5. B, non-labeled CS-D competed the binding of
[3H]CS-D to the column. The arrows in
A and B indicate the change to pH 11.5 buffer. To
enrich DSD-1 epitope-bearing carbohydrates, CS-C and CS-D were loaded
repetitively on a mAb 473HD affinity column as described under
"Experimental Procedures" (CS-C affinity retained fraction of the
first, second, and third chromatographies were named C-FR 1, C-FR 2, and C-FR3, respectively; C-FR UB represents the unbound fraction;
likewise the corresponding fractions with CS-D were named D-FR 1, D-FR
2, D-FR 3, and D-FR UB, respectively). The eluted fractions were
analyzed by competition ELISA using different concentrations of
competitors. C shows the analysis of the eluted fractions of
CS-C and D of CS-D. The highest DSD-1 epitope-enriched
fractions interfered with the binding of mAb 473HD to the DSD-1-PG,
whereas the lowest affinity fractions did not. Note, the CS-D fractions
inhibited the binding at lower concentrations as compared with CS-C
fractions. The percent inhibition was calculated as follows: % inhibition = [(ODtest ODcontrol)/ODcontrol ] × 100.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Disaccharide composition of the CS-C or CS-D subfractions obtained by
immunoaffinity chromatography
Each fraction was digested completely with chondroitinase ABC, and the
products were identified and quantified by HPLC as described under
"Experimental Procedures."
|
|
The eluted fractions were tested at different concentrations in
competition ELISAs. CS-D enriched for the DSD-1 epitope inhibited the
binding of mAb 473HD to DSD-1-PG at lower concentrations than the
equivalent CS-C fractions (Fig. 4, C and D). This
indicates that the DSD-1 epitope represents a larger fraction of CS-D
carbohydrates as compared with CS-C.
Analysis of Chondroitin Sulfate Chains Attached to
DSD-1-PG--
Chondroitinase ABC lyase digestion of the purified
DSD-1-PG yielded four disaccharide units (a)
HexA 1-3GalNAc, (b)
HexA 1-3GalNAc(6-O-sulfate), (c)
HexA 1-3GalNAc(4-O-sulfate), and (d)
HexA(2-O-sulfate) 1-3GalNAc(6-O-sulfate) and (e) an unidentified compound with recoveries
of 2.3, 23.2, 67.6, 5.0, and 2.0%, respectively, as quantified by HPLC
(Fig. 5A). Furthermore, the
structure of each peak was identified by digestion with sulfatases.
Peak b [ HexA 1-3GalNAc(6-O-sulfate)] and
peak d
[ HexA(2-O-sulfate) 1-3GalNAc(6-O-sulfate)]
in Fig. 5A were shifted to the position of peaks
a [ HexA 1-3GalNAc] and f
[ HexA(2-O-sulfate) 1-3GalNAc], respectively, upon
chondro-6-sulfatase digestion (Fig. 5B), confirming that the
GalNAc residues of the compounds in peaks b and d
were sulfated at the C-6 position. The nature of peak e,
which was resistant to chondro-6-sulfatase, hence is not
[ HexA 1-3GalNAc(4, 6-di-O-sulfate)], remains to be
determined. Peak d
[ HexA(2-O-sulfate) 1-3GalNAc(6-O-sulfate)] was shifted to the position of peak b
[ HexA 1-3GalNAc(6-O-sulfate)] upon
hexuronate-2-O-sulfatase digestion, confirming that the HexA residue of the compound in peak d was
sulfated at C-2 position (Fig. 5C). The peaks observed
before peak a in Fig. 5, A C, were attributable
to buffer salts. The results altogether indicate that the DSD-1-PG
bears chondroitin sulfate chains that are composed of disaccharide
units including GlcUA-GalNAc (unsulfated disaccharides), GlcUA-GalNAc(6S) (CS-C), GlcUA-GalNAc(4S) (CS-A), and
GlcUA(2S)-GalNAc(6S) (CS-D). Thus, the rare CS-D unit was clearly
demonstrated in the DSD-1-PG being consistent with the higher
proportion of the D disaccharide in the high affinity fractions
(D-FR 1, D-FR 2, and C-FR 1 in Table I).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 5.
HPLC analysis of GAGs of the DSD-1-PG.
The DSD-1-PG was incubated with chondroitinase ABC (A),
chondroitinase ABC, and then chondro-6-sulfatase (B), or
chondroitinase ABC and then hexuronate-2-sulfatase (C),
and each reaction mixture was analyzed by HPLC on an amine-bound silica
column as described under "Experimental Procedures." Peak
a, HexA 1-3GalNAc; peak b,
HexA 1-3GalNAc(6S); peak c, HexA 1-3GalNAc(4S);
peak d, HexA(2S) 1-3GalNAc(6S); peak e,
unidentified material; peak f, HexA(2S) 1-3GalNAc. The
elution positions of the standard disaccharides are indicated in
A as follows: 1, HexA 1-3GalNac;
2, HexA 1-3GalNac(6-O-sulfate);
3, HexA 1-3GalNAc(4-O-sulfate);
4,
HexA(2-O-sulfate) 1-3GalNAc(6-O-sulfate);
5, HexA 1-3GalNAc(4,6-O-disulfate);
6,
HexA(2-O-sulfate) 1-3GalNAc(4,6-O-disulfate).
|
|
GAGs Containing the DSD-1 Epitope Promote Neurite Outgrowth When
Presented as Substrate--
It has been shown previously that the
DSD-1 structure is involved in the neurite outgrowth-promoting capacity
of substrate-bound DSD-1-PG (18). To test whether DSD-1
epitope-carrying GAG chains are able to promote neurite outgrowth, E18
hippocampal neurons were cultured in low density on glass coverslips
coated with PORN and different carbohydrate preparations. As shown
previously, the fraction of neurite-bearing cells increased on
coverslips coated with CS-D (61%) compared with the number of neurons
with processes cultured on CS-A, CS-B, and CS-C (45, 42, and 46%,
respectively) or on PORN (38%) alone (38). The present morphometric
analysis showed that not only the number of neurite-bearing cells but
also the length of the longest neurites was enhanced on CS-D
versus the other members of the chondroitin sulfate family
(Figs. 6 an 7A). Although the
promotion of neurite length on CS-D was
not as strong as the effect obtained with the integral DSD-1-PG, it was
significantly inhibited by mAb 473HD when added to the culture medium
(Fig. 7B). This indicates that GAGs are able to promote neurite outgrowth of hippocampal neurons although the carbohydrate chains are not linked to a protein such as the DSD-1-PG core protein and that the neurite outgrowth-promoting activity of CS-D is linked to
the DSD-1 epitope.

View larger version (84K):
[in this window]
[in a new window]
|
Fig. 6.
Neurite outgrowth promotion by different
chondroitin sulfate isoforms. E18 hippocampal neurons were
cultured on glass coverslips coated with PORN and CS-A (A),
CS-B (B), CS-C (C), and CS-D (D), and
on PORN alone (E). The cells were stained for tubulin after
24 h in culture. Note the increased neurite lengths on CS-D.
Bar, 35 µm.
|
|

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 7.
Length distribution of neurites of
hippocampal neurons cultured on chondroitin sulfate substrates.
Neurites were morphometrically analyzed after hippocampal neurons had
been cultured on different chondroitin sulfate isoforms without
(A) or in the presence of mAb 473HD for 24 h
(B). The lengths of the longest neurites of 100 neurite-bearing cells were measured in three independent experiments.
Graph A shows the percent increase of the mean length of the
longest neurites versus the PORN control. CS-D promoted
neurite outgrowth as compared with the Porn control. Graph B
shows the percent increase of the mean length of the longest neurites
in the presence of mAb 473HD versus the length in the
absence of antibody. mAb 473HD inhibited the neurite
outgrowth-promoting effect of CS-D. In both experiments percentages
were calculated as follows: % increase = [(Ltest Lcontrol)/Lcontrol] × 100 (where L indicates length). Statistical analysis of the
pooled data was evaluated with the Mann-Whitney U test.
n.s., not significant; *0.01 p < 0.05; ***,
p > 0.001.
|
|
The DSD-1 Epitope Is Sufficient to Promote Neurite
Outgrowth--
To study whether the DSD-1 structure is sufficient to
promote neurite outgrowth, fractions enriched for the DSD-1 epitope were tested as substrates for hippocampal neurons, and the number of
neurite-bearing cells was determined. The DSD-1 epitope-enriched fractions (C-FR 1, C-FR 2, C-FR 3, and C-FR UB; D-FR 1, D-FR 2, D-FR 3, and D-FR UB) rather than the chondroitin sulfate
mixtures were used, because the biochemical analysis had revealed
varying concentrations of the DSD-1 epitope in the latter. DSD-1
epitope-enriched fractions obtained from CS-C and CS-D promoted neurite
outgrowth more efficiently than the carbohydrate fractions that were
not retained on the mAb 473HD affinity column (Fig.
8, A and B). In the
case of CS-C, the number of neurite-bearing cells on the DSD-1 epitope-enriched fraction C-FR 1 was statistically higher than on the
unprocessed CS-C (59 versus 46%). However, the fraction of
neurite-bearing cells on CS-D preparations was not statistically different when compared with the DSD-1 epitope-enriched fractions D-FR
1 and D-FR 2 (61 versus 61 and 63%, respectively) obtained therefrom, indicating that the content of DSD-1 epitope in CS-D and
D-FR 1 and D-FR 2 is at saturation with respect to the neurite outgrowth-promoting effect under these conditions (coating 16 µg/ml
as total weight or 5 µg/ml as GlcUA). These results show that the
neurite outgrowth-promoting capacity of both CS-C and CS-D correlates
with the content of CS-D units and the DSD-1 epitope in these
preparations.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 8.
Promotion of neurite outgrowth of hippocampal
neurons by chondroitin sulfates bearing the DSD-1 epitope. DSD-1
epitope-enriched fractions (see Fig. 4) were tested as substrates for
hippocampal neurons as described in Fig. 6, and the percentage of
neurite-bearing cells was determined. A, C-FR 1 promoted
neurite outgrowth significantly stronger than C-FR 2, C-FR 3, C-Fr UB,
and CS-C. The effects of these fractions were not significantly
different. B, fractions D-FR 1 and D-FR 2 could not promote
neurite outgrowth more extensively than the original CS-D preparation.
In contrast, the effect of D-FR UB was significantly less as compared
with CS-D, D-FR1, and D-FR 2. The number of experiments is
given in parentheses. 100 cells were counted per experiment.
Statistical analysis was evaluated with the Mann-Whitney U
test. Only the significant differences are indicated. *, 0.01 < p < 0.05; **, 0.001 < p < 0.01.
|
|
This observation is supported by the functional analysis of the
desulfated fractions. The neurite outgrowth-promoting capacity of the
least desulfated fraction DS 1 was not significantly reduced in
comparison to CS-D (52 versus 61%). Progressive
desulfation, however, resulted in the loss of neurite
outgrowth-promoting properties of the fraction DS 2 and DS 3 (33 and
35% of process-bearing neurons, respectively). This functional
inactivation parallels and thus reflects the loss of the DSD-1 epitope
as evidenced by the competition ELISA described above (Table
II). To ascertain that the DSD-1 epitope
that is abolished by desulfation is a causative structure in neurite
outgrowth promotion, E18 hippocampal neurons were grown on CS-D in the
presence of mAb 473HD which recognizes the epitope in a
sulfation-dependent manner. As expected, mAb 473HD
specifically neutralized the neurite outgrowth-promoting activity of
CS-D (Fig. 7B).
View this table:
[in this window]
[in a new window]
|
Table II
Analysis of desulfated CS-D fractions
The pyridinium salt of CS-D was progressively desulfated by chemical
procedures. The desulfated fractions were analyzed by competition ELISA
with mAb 473HD on immobilized DSD-1-PG. The least desulfated CS-D
fraction DS 1 inhibited the binding of mAb 473HD to DSD-1-PG more
prominently than the most extensively desulfated DS 3. The data
represent one experiment. All values were done in triplicate. In
addition, the desulfated CS-D preparations were tested as substrates
for hippocampal neurons as described in Fig. 4, and the percentage of
neurite-bearing cells was determined. The most desulfated preparation
of CS-D could not promote neurite outgrowth as effectively as the less
desulfated ones or unmodified CS-D, indicating that sulfation is
necessary for mediating the neurite outgrowth promoting effect. At
least four independent experiments were done. 100 cells were counted
per experiment. Statistical analysis was evaluated versus CS
D with the Mann-Whitney U test. NS, not significant.
|
|
Hence, the DSD-1 structure by itself appears to be sufficient to
promote neurite outgrowth of hippocampal neurons, also in a situation
where the GAGs are not bound to the DSD-1-PG core protein.
 |
DISCUSSION |
In the present study the structural and functional properties of
the DSD-1 epitope, a chondroitin sulfate variant recognized by mAb
473HD, were examined. The DSD-1 epitope displays a restricted tissue
distribution and is preferentially expressed in the central nervous
system of the adult mouse. Structurally, it is associated with the
D motif and depends on sulfation of carbohydrate polymers that are comprised in CS-C and CS-D preparations. Culture substrates prepared with carbohydrate fractions enriched for the DSD-1 epitope promote neurite outgrowth of hippocampal neurons, a property that is
neutralized by mAb 473HD. We propose that carbohydrates of the
chondroitin sulfate family contain discrete structural motifs with
functional properties, such as the DSD-1 epitope. To exert their
physiological functions, these domains might interact with specific
cellular receptors.
The DSD-1-PG has initially been identified using the mAb 473HD and
shown to be expressed by immature glial cells of the central nervous
system (18, 65). Western blotting experiments conducted with octyl
glucoside extracts of several adult mouse organs indicated that the
DSD-1 epitope is mainly expressed in the cerebellum and the
telencephalon but not in various non-neural tissues, different from
other mAbs such as CS-56 which recognize chondroitin sulfate epitopes
(67). In view of the involvement in the neurite outgrowth-promoting effect of substrate-bound DSD-1-PG (18) and the lineage-related, restricted expression (18, 65), the structural characteristics of the
DSD-1 epitope were examined. Confirming earlier studies, mAb 473HD
recognized epitopes on CS-C and CS-D but not on CS-A, CS-B, and CS-E
(18, 38). These GAG structures differ by the relative positions of
sulfate groups in the dimeric building blocks. A sulfate dependence of
the DSD-1 epitope is highlighted by the finding that the inhibition of
sulfation of newly synthesized GAG chains in vitro and the
chemical de-sulfation of CS-D both abolished the binding site of mAb
473HD. It was possible to enrich DSD-1 epitope-bearing sugars from CS-C
and CS-D by affinity chromatography, which suggests that not all but a
subset of carbohydrates contain the epitope. These DSD-1
epitope-enriched fractions were also rich in D disaccharide units.
Other than in shark cartilage, the D unit is rarely detected in animal
tissues (68, 69). Interestingly, a trace of D disaccharides has been
found in the developing rat cerebellum (70). Recent structural studies
provided evidence that CS-D polymers are composed of defined sequences
of disaccharide building blocks, such as -A-D-A- (38, 42, 43). So
far, it was not possible to link one of the identified CS-D
carbohydrate sequences to the DSD-1 epitope, because mAb 473HD
recognizes only polymers longer than
tetradecasaccharides.3 These
results in conjunction with the present data support the view that the
DSD-1 epitope represents a particular structure detectable in CS-C and
CS-D preparations which is associated with the D unit. Consistent with
this notion, the rare D unit was detected in DSD-1-PG preparations,
although the concentration proved lower than in the DSD-1
epitope-enriched fractions obtained from other sources. This could be
due to a confinement of D units to the DSD-1 epitope of DSD-1-PG,
whereas these might be distributed to several other domains in CS-C and
CS-D polymers. The sequence of disaccharide units which constitutes the
DSD-1 epitope in conjunction with the D motif remains to be
clarified.
Because indirect evidence suggested that the DSD-1 epitope is required
for the neurite outgrowth-promoting activity of substrate-bound DSD-1-PG (18), the functional activities of chondroitin sulfates were
examined in a neurite outgrowth assay. The carbohydrate CS-D, but not
CS-A, CS-B, and CS-C, which possess the same carbohydrate backbone
structure with sulfation patterns different from that of CS-D,
significantly increased the fraction of neurite-bearing cells (38) and
the mean length of the longest neurites. In addition CS-E, which was
not identified in DSD-1-PG preparations, stimulated neurite extension
in this assay. Yet, mAb 473HD neutralized the neurite
outgrowth-stimulating effect of CS-D but did not affect the neurons
cultured on the other GAGs, suggesting that CS-E acts in a DSD-1
epitope-independent manner.2 Although both CS-D and CS-E
species contain di- and/or tri-sulfated disaccharide units (61, 62), we
assume that the arrangement of sulfate groups, but not
merely charge density on the carbohydrate backbone, is important for
the neurite outgrowth-promoting effect. This implies that a particular
arranged pattern of sulfate groups on a larger backbone is crucial for
the DSD-1 epitope, in agreement with the sulfate dependence of the
latter. Furthermore, the existence of sulfate-based neurite
growth-promoting motifs other than the DSD-1 epitope, e.g.
in CS-E, seems possible. In support of this interpretation, the
relative concentration of the DSD-1 structure in chondroitin sulfates
was found to vary, with a stronger reactivity of mAb 473HD for CS-D as
compared with CS-C. The DSD-1 epitope-enriched fractions derived from
CS-C and CS-D by affinity chromatography displayed a
concentration-dependent activity in that the highest affinity fractions promoted neurite growth more efficiently than the
unbound ones. The active carbohydrates contained an elevated proportion
of D disaccharide units, which supports the conclusion that D units are
of critical significance for the constitution of the neurite
outgrowth-promoting DSD-1 epitope. In view of the asserted functional
significance of sulfation, it is of interest to consider potential
neuritogenic influences of heparin and heparan sulfate, which carry
comparable sulfate charges than chondroitin sulfates. It has been shown
that these GAGs exert influences on neurite outgrowth patterns of
several types of central nervous system neurons, yet the effects were
clearly distinct from those obtained with chondroitin sulfates. For
example, heparin favored the extension of axons, whereas CS-B or
derived fragments sustained the growth of both dendrites and axons (21,
22). This finding emphasizes that chondroitin sulfate
effects on neurite growth are selective and correlated with particular
carbohydrate motifs, which are defined by specific sulfation
patterns.
Several studies concluded that chondroitin sulfates are organized in
domains. This assumption is based on structural analysis, for example
of CS-D (38, 42, 43), and on the immunohistological analysis of mAbs
generated against chondroitin sulfates (44, 45, 71, 72). These
different mAbs yielded distinct spatial and temporal staining profiles
in developing and in lesioned neural tissues (39, 40, 46). One further
example is provided by the neurite outgrowth-promoting DSD-1 epitope,
which is expressed in regions of intense axon growth in
vivo, e.g. the inter-rhombomeric boundaries of the
chicken hindbrain (73). This property contrasts the proposed inhibitory
action of chondroitin sulfates reported in other systems (25-29). Most
of the latter studies, however, were carried out with CS-A, CS-B, and
CS-C but not with CS-D preparations that contain a sufficient
concentration of DSD-1 epitope to promote neurite growth. After lesions
of the central nervous system chondroitin sulfates including the DSD-1
epitope are up-regulated in the region of the glial scar, where these
carbohydrates are supposed to contribute to the prevention of
regeneration (30, 32-36). Recently, a DSD-1 epitope-bearing
chondroitin sulfate proteoglycan with neurite growth inhibiting
properties related to phosphacan was described as a ligand for
tenascin-R (74). On the other hand, the DSD-1 epitope is up-regulated
in the regenerating lesioned peripheral nervous system (40).
Considering its concentration dependence, it is conceivable that other
inhibitory molecules or motifs of the same molecule override the
neurite outgrowth-promoting activity of the DSD-1 epitope.
In order to substantiate the hypothesis that chondroitin sulfate
domains are organized in functional domains, the enzymes and
biosynthetic pathways generating structures such as the DSD-1 epitope
have to be uncovered. Another implication of the concept resides in the
necessity of complementary receptors that would decipher specific
information contained in GAG chains and mediate selective cellular
responses. In the case of heparan sulfate, specific ligands of
characterized domain structures have been defined (Ref. 75; for review
see Ref. 76). It has been reported that heparin by itself activates a
receptor tyrosine kinase (77). Thus, it is conceivable that also the
DSD-1 epitope might elicit second messenger responses which finally
lead to a stimulation of neurite growth.
 |
ACKNOWLEDGEMENTS |
We thank Dr. J. Trotter for the gift of the
cell line Oli-neu and Prof. W. B. Huttner for ongoing support.
Critical comments on the manuscript by Dr. A. B. Clement, Dr. J. Garwood, Dr. M. Jouet, and K. Schütte are gratefully
acknowledged.
 |
FOOTNOTES |
*
This work was supported by the German Research Council Grant
DFG Fa 159/5-1, -2, -3 and in part by the Science Research Promotion Fund from The Japan Private School Promotion Foundation, the Sasakawa Scientific Research Grant from the Japan Science Society, a grant from
Hyogo Science and Technology, Grants-in-aid for Scientific Research on
Priority Areas 10178102, Scientific Research (B) 09470509, and
International Scientific Research (Joint Research) 09044345 from the
Ministry of Education, Science, Sports and Culture of Japan.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Recipient of an H.-L. Schilling Professorship for
Neuroscience. To whom correspondence should be addressed: Dept. of
Neurobiology, University of Heidelberg, Im Neuenheimer Feld 364, D-69120 Heidelberg, Germany. Tel.: 49-6221-5467; Fax: 49-6221-548301;
E-mail: faissner{at}sun0.urz.uni-heidelberg.de.
The abbreviations used are:
ECM, extracellular
matrix; GAG, glycosaminoglycan; PG, proteoglycan; E18, embryonic day
18; PBS, phosphate-buffered saline; PBST, PBS and 0.05% Tween 20; BSA, bovine serum albumin; ELISA, enzyme-linked immunosorbent assay; PORN, poly-DL-ornithineHPLC, high pressure liquid
chromatography HexA, 4,5 unsaturated hexuronic acid.
2
A. Clement and A. Faissner, unpublished
results.
3
S. Nadanaka, K. Sugahara, A. Clement, and A. Faissner, unpublished results.
 |
REFERENCES |
-
Letourneau, P. C.,
Condic, M. L.,
and Snow, D. M.
(1992)
Curr. Opin. Gen. & Dev.
2,
625-634[CrossRef][Medline]
[Order article via Infotrieve]
-
Reichardt, L. F.,
and Tomaselli, K. J.
(1991)
Annu. Rev. Neurosci.
14,
531-570[CrossRef][Medline]
[Order article via Infotrieve]
-
Ruoslahti, E.
(1989)
J. Biol. Chem.
264,
13369-13372[Free Full Text]
-
Miao, H.,
Ishai-Michaeli, R.,
Atzmon, R.,
Peretz, T.,
and Vlodavsky, I.
(1996)
J. Biol. Chem.
271,
4879-4886[Abstract/Free Full Text]
-
Roskelley, C. D.,
Srebrow, A.,
and Bissell, M. J.
(1995)
Curr. Opin. Cell Biol.
7,
736-747[CrossRef][Medline]
[Order article via Infotrieve]
-
Sanes, J. R.
(1989)
Annu. Rev. Neurosci.
12,
491-516[CrossRef][Medline]
[Order article via Infotrieve]
-
Faissner, A.,
Götz, B.,
Joester, A.,
Wigger, F.,
Scholze, A.,
and Schütte, K.
(1996)
Semin. Neurosci.
8,
347-356
-
Faissner, A.
(1997)
Cell Tissue Res.
290,
331-341[CrossRef][Medline]
[Order article via Infotrieve]
-
Kjellen, L.,
and Lindahl, U.
(1991)
Annu. Rev. Biochem.
60,
443-475[CrossRef][Medline]
[Order article via Infotrieve]
-
Grumet, M.,
Friedlander, D. R.,
and Sakurai, T.
(1996)
Perspect. Dev. Neurobiol.
3,
319-330[Medline]
[Order article via Infotrieve]
-
Lander, A. D.
(1993)
Curr. Opin. Neurobiol.
3,
716-723[CrossRef][Medline]
[Order article via Infotrieve]
-
Rauch, U.,
Gao, P.,
Janetzko, A.,
Flaccus, A.,
Hilgenberg, L.,
Tekotte, H.,
Margolis, R. K.,
and Margolis, R. U.
(1991)
J. Biol. Chem.
266,
14785-14801[Abstract/Free Full Text]
-
Rauch, U.,
Karthikeyan, L.,
Maurel, P.,
Margolis, R. U.,
and Margolis, R. K.
(1992)
J. Biol. Chem.
267,
19536-19547[Abstract/Free Full Text]
-
Milev, P.,
Friedlander, D. R.,
Sakurai, T.,
Karthikeyan, L.,
Flad, M.,
Margolis, R. K.,
Grumet, M.,
and Margolis, R. U.
(1994)
J. Cell Biol.
127,
1703-1715[Abstract/Free Full Text]
-
Grumet, M.,
Flaccus, A.,
and Margolis, R. U.
(1993)
J. Cell Biol.
120,
815-824[Abstract/Free Full Text]
-
Friedlander, D. R.,
Milev, P.,
Karthikeyan, L.,
Margolis, R. K.,
Margolis, R. U.,
and Grumet, M.
(1994)
J. Cell Biol.
125,
669-680[Abstract/Free Full Text]
-
Iijima, N.,
Oohira, A.,
Mori, T.,
Kitabatake, K.,
and Kohsaka, S.
(1991)
J. Neurochem.
56,
706-708[Medline]
[Order article via Infotrieve]
-
Faissner, A.,
Clement, A.,
Lochter, A.,
Streit, A.,
Mandl, C.,
and Schachner, M.
(1994)
J. Cell Biol.
126,
783-799[Abstract/Free Full Text]
-
Deller, T.,
Haas, C. A.,
Naumann, T.,
Joester, A.,
Faissner, A.,
and Frotscher, M.
(1997)
Neuroscience
81,
829-846[CrossRef][Medline]
[Order article via Infotrieve]
-
Brittis, P.,
Canning, D.,
and Silver, J.
(1992)
Science
255,
733-736[Abstract/Free Full Text]
-
Lafont, F.,
Rousselet, A.,
Valenza, C.,
Petitou, M.,
Pascal, M.,
Rouget, M.,
and Prochiantz, A.
(1994)
Dev. Biol.
165,
453-468[CrossRef][Medline]
[Order article via Infotrieve]
-
Lafont, F.,
Rouget, M.,
Triller, A.,
Prochiantz, A.,
and Rousselet, A.
(1992)
Development
114,
17-29[Abstract]
-
Kappler, J.,
Junghans, U.,
Koops, A.,
Stichel, C. C.,
Hausser, H.-J.,
Kresse, H.,
and Müller, H. W.
(1997)
Eur. J. Neurosci.
9,
306-318[CrossRef][Medline]
[Order article via Infotrieve]
-
Gates, M.,
Fillmore, H.,
and Steindler, D. A.
(1996)
J. Neurosci.
16,
8005-8018[Abstract/Free Full Text]
-
Dou, C.-L.,
and Levine, J. M.
(1995)
J. Neurosci.
15,
8053-8066[Abstract]
-
Smith-Thomas, L. C.,
Fok-Seang, J.,
Stevens, J.,
Du, J. S.,
Muir, E.,
Faissner, A.,
Geller, H. M.,
Rogers, J. H.,
and Fawcett, J. W.
(1994)
J. Cell Sci.
107,
1687-1695[Abstract]
-
Snow, D. M.,
Brown, E. M.,
and Letourneau, P. C.
(1996)
Int. J. Dev. Neurosci.
14,
331-349[CrossRef][Medline]
[Order article via Infotrieve]
-
Verna, J.-M.,
Fichard, A.,
and Saxod, R.
(1989)
Int. J. Dev. Neurosci.
7,
389-399[CrossRef][Medline]
[Order article via Infotrieve]
-
Yamada, H.,
Fredette, B.,
Shitara, K.,
Hagihara, K.,
Miura, R.,
Ranscht, B.,
Stallcup, W. B.,
and Yamaguchi, Y.
(1997)
J. Neurosci.
17,
7784-7795[Abstract/Free Full Text]
-
Steindler, D. A.,
O'Brien, T. F.,
Laywell, E.,
Harrington, K.,
Faissner, A.,
and Schachner, M.
(1990)
Exp. Neurobiol.
109,
35-56
-
Faissner, A.,
and Steindler, D.
(1995)
Glia
13,
233-254[CrossRef][Medline]
[Order article via Infotrieve]
-
Bovolenta, P.,
Wandosell, F.,
and Nieto-Sampedro, M.
(1993)
Neuroreport
5,
345-348[Medline]
[Order article via Infotrieve]
-
Davies, S. J. A.,
Fitch, M. T.,
Memberg, S. P.,
Hall, A. K.,
Raisman, G.,
and Silver, J.
(1997)
Nature
390,
680-683[Medline]
[Order article via Infotrieve]
-
Lips, K.,
Stichel, C.,
and Müller, H. W.
(1995)
J. Neurocytol.
24,
449-464[CrossRef][Medline]
[Order article via Infotrieve]
-
Pindzola, R. R.,
Doller, C.,
and Silver, J.
(1993)
Dev. Biol.
156,
34-48[CrossRef][Medline]
[Order article via Infotrieve]
-
McKeon, R. J.,
Schreiber, R. C.,
Rudge, J. S.,
and Silver, J.
(1991)
J. Neurosci.
11,
3398-3411[Abstract]
-
Fernaud-Espinosa, I.,
Nieto-Sampedro, M.,
and Bovolenta, P.
(1994)
J. Cell Sci.
107,
1437-1448[Abstract]
-
Nadanaka, S.,
Clement, A.,
Masayama, K.,
Faissner, A.,
and Sugahara, K.
(1998)
J. Biol. Chem.
273,
3296-3307[Abstract/Free Full Text]
-
Shum, D. K. Y.,
and Chau, C. H.
(1996)
J. Neurosci. Res.
46,
465-476[CrossRef][Medline]
[Order article via Infotrieve]
-
Braunewell, K.-H.,
Martini, R.,
LeBaron, R.,
Kresse, H.,
Faissner, A.,
Schmitz, B.,
and Schachner, M.
(1995)
Eur. J. Neurosci.
7,
792-804[CrossRef][Medline]
[Order article via Infotrieve]
-
Challocombe, J. F.,
and Elam, J. S.
(1995)
Exp. Neurol.
134,
126-134[CrossRef][Medline]
[Order article via Infotrieve]
-
Sugahara, K.,
Nadanaka, S.,
Takeda, K.,
and Kojima, T.
(1996)
Eur. J. Biochem.
239,
871-880[Medline]
[Order article via Infotrieve]
-
Sugahara, K.,
and Kojima, T.
(1996)
Eur. J. Biochem.
239,
865-870[Medline]
[Order article via Infotrieve]
-
Sorrell, J. M.,
Mahmoodian, F.,
Schafer, I. A.,
Davis, B.,
and Caterson, B.
(1990)
J. Histochem. Cytochem.
38,
393-402[Abstract]
-
Mark, M. P.,
Baker, J. R.,
Kimata, K.,
and Ruch, J.-V.
(1990)
Int. J. Dev. Biol.
34,
191-204[Medline]
[Order article via Infotrieve]
-
Fernaud-Espinosa, I.,
Nieto-Sampedro, M.,
and Bovolenta, P.
(1996)
J. Neurobiol.
30,
410-424[CrossRef][Medline]
[Order article via Infotrieve]
-
Goslin, K.,
and Banker, G.
(1991)
in
Culturing Nerve Cells (Banker, G., and Goslin, K., eds), pp. 251-281, MIT Press, Cambridge, MA
-
Kempf, M.,
Clement, A.,
Faissner, A.,
Lee, G.,
and Brandt, R.
(1996)
J. Neurosci.
16,
5583-5592[Abstract/Free Full Text]
-
Bottenstein, J. E.,
and Sato, G. H.
(1979)
Proc. Natl. Acad. Sci. U. S. A.
76,
514-517[Abstract/Free Full Text]
-
Schnitzer, J.,
and Schachner, M.
(1981)
J. Neuroimmunol.
1,
471-487[CrossRef][Medline]
[Order article via Infotrieve]
-
Jung, M.,
Krämer, E.,
Grzenkowski, M.,
Tang, K.,
Blakemore, W.,
Aguzzi, A.,
Khazie, K.,
von Blankenfeld, G.,
Kettenmann, H.,
and Trotter, J.
(1995)
Eur. J. Neurosci.
7,
1245-1265[CrossRef][Medline]
[Order article via Infotrieve]
-
Faissner, A.,
and Kruse, J.
(1990)
Neuron
5,
627-637[CrossRef][Medline]
[Order article via Infotrieve]
-
Faissner, A.,
Teplow, D.,
Kübler, D.,
Keilhauer, G.,
Kinzel, V.,
and Schachner, M.
(1985)
EMBO J.
4,
3105-3113[Medline]
[Order article via Infotrieve]
-
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
-
Towbin, H.,
Staehlin, T.,
and Gordon, J.
(1979)
Proc. Natl. Acad. Sci. U. S. A.
75,
4350-4354
-
Blumenkrantz, N.,
and Asboe-Hansen, G.
(1973)
Anal. Biochem.
54,
484-489[CrossRef][Medline]
[Order article via Infotrieve]
-
Bitter, T.,
and Muir, H. M.
(1962)
Anal. Biochem.
4,
330-334[CrossRef][Medline]
[Order article via Infotrieve]
-
Nagasawa, K.,
Inoue, Y.,
and Kamata, T.
(1977)
Carbohydr. Res.
58,
47-55[CrossRef][Medline]
[Order article via Infotrieve]
-
Hook, M.,
Riesenfeld, J.,
and Lindahl, U.
(1982)
Anal. Biochem.
119,
236-245[CrossRef][Medline]
[Order article via Infotrieve]
-
Dmitriev, B. A.,
Knirel, Y. A.,
and Kocketkov, N. K.
(1973)
Carbohydr. Res.
29,
451-457[CrossRef]
-
Takasaki, S.,
Miyuochi, T.,
and Kobata, A.
(1982)
Methods Enzymol.
83,
263-268[Medline]
[Order article via Infotrieve]
-
Sugahara, K.,
Shigeno, K.,
Masuda, M.,
Fujii, N.,
Kurosaka, A.,
and Takeda, K.
(1994)
Carbohydr. Res.
255,
145-163[CrossRef][Medline]
[Order article via Infotrieve]
-
Sugahara, K.,
Okumura, Y.,
and Yamashina, I.
(1989)
Biochem. Biophys. Res. Commun.
162,
189-197[CrossRef][Medline]
[Order article via Infotrieve]
-
Yoshida, K.,
Miyauchi, S.,
Kikuchi, H.,
Tawada, A.,
and Tokuyasu, K.
(1989)
Anal. Biochem.
177,
327-332[CrossRef][Medline]
[Order article via Infotrieve]
-
Schnädelbach, O.,
Mandl, C.,
and Faissner, A.
(1998)
Glia
23,
99-119[CrossRef][Medline]
[Order article via Infotrieve]
-
Baeuerle, P. A.,
and Huttner, W. B.
(1986)
Biochem. Biophys. Res. Commun.
141,
870-877[CrossRef][Medline]
[Order article via Infotrieve]
-
Avnur, Z.,
and Geiger, B.
(1984)
Cell
38,
811-822[CrossRef][Medline]
[Order article via Infotrieve]
-
Davidson, S.,
Gilead, L.,
Amira, M.,
Ginsburg, H.,
and Razin, E.
(1990)
J. Biol. Chem.
265,
12324-12330[Abstract/Free Full Text]
-
Iwata, H.
(1969)
Nippon Seikeigeka Gakkai Zasshi
43,
455-473[Medline]
[Order article via Infotrieve]
-
Flaccus, A.,
Janetzko, A.,
Tekotte, H.,
Margolis, R. K.,
and Margolis, R. U.
(1991)
J. Neurochem.
56,
1608-1615[CrossRef][Medline]
[Order article via Infotrieve]
-
Caterson, B.,
Mahmoodian, F.,
Sorrell, J. M.,
Hardingham, T. E.,
Bayliss, M. T.,
Carney, S. L.,
Ratcliffe, A.,
and Muir, H.
(1990)
J. Cell Sci.
97,
411-417[Abstract/Free Full Text]
-
Perris, R.,
Krotoski, D.,
Lallier, T.,
Domingo, C.,
Sorrell, J. M.,
and Bronner-Fraser, M.
(1991)
Development
111,
583-599[Abstract]
-
Heyman, I.,
Faissner, A.,
and Lumsden, A.
(1995)
Dev. Dyn.
204,
301-315[Medline]
[Order article via Infotrieve]
-
Xiao, Z.-C.,
Bartsch, U.,
Margolis, R. K.,
Rougon, G.,
Montag, D.,
and Schachner, M.
(1997)
J. Biol. Chem.
272,
32092-32101[Abstract/Free Full Text]
-
Maccarana, M.,
Casu, B.,
and Lindahl, U.
(1993)
J. Biol. Chem.
268,
23898-23905[Abstract/Free Full Text]
-
Salmivirta, M.,
Lindolt, K.,
and Lindahl, U.
(1996)
FASEB J.
10,
1270-1279[Abstract]
-
Gao, G.,
and Goldfarb, M.
(1995)
EMBO J.
14,
2183-2190[Medline]
[Order article via Infotrieve]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. Akita, A. von Holst, Y. Furukawa, T. Mikami, K. Sugahara, and A. Faissner
Expression of Multiple Chondroitin/Dermatan Sulfotransferases in the Neurogenic Regions of the Embryonic and Adult Central Nervous System Implies That Complex Chondroitin Sulfates Have a Role in Neural Stem Cell Maintenance
Stem Cells,
March 1, 2008;
26(3):
798 - 809.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Fongmoon, A. K. Shetty, Basappa, S. Yamada, M. Sugiura, P. Kongtawelert, and K. Sugahara
Chondroitinase-mediated Degradation of Rare 3-O-Sulfated Glucuronic Acid in Functional Oversulfated Chondroitin Sulfate K and E
J. Biol. Chem.,
December 21, 2007;
282(51):
36895 - 36904.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Yamaguchi, S. Ohtake, K. Kimata, and O. Habuchi
Molecular Cloning of Squid N-Acetylgalactosamine 4-Sulfate 6-O-Sulfotransferase and Synthesis of a Unique Chondroitin Sulfate Containing E D Hybrid Tetrasaccharide Structure by the Recombinant Enzyme
Glycobiology,
December 1, 2007;
17(12):
1365 - 1376.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Pothacharoen, K. Kalayanamitra, S. S. Deepa, S. Fukui, T. Hattori, N. Fukushima, T. Hardingham, P. Kongtawelert, and K. Sugahara
Two Related but Distinct Chondroitin Sulfate Mimetope Octasaccharide Sequences Recognized by Monoclonal Antibody WF6
J. Biol. Chem.,
November 30, 2007;
282(48):
35232 - 35246.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Yamada, H. Morimoto, T. Fujisawa, and K. Sugahara
Glycosaminoglycans in Hydra magnipapillata (Hydrozoa, Cnidaria): demonstration of chondroitin in the developing nematocyst, the sting organelle, and structural characterization of glycosaminoglycans
Glycobiology,
August 1, 2007;
17(8):
886 - 894.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Purushothaman, J. Fukuda, S. Mizumoto, G. B. ten Dam, T. H. van Kuppevelt, H. Kitagawa, T. Mikami, and K. Sugahara
Functions of Chondroitin Sulfate/Dermatan Sulfate Chains in Brain Development: CRITICAL ROLES OF E AND iE DISACCHARIDE UNITS RECOGNIZED BY A SINGLE CHAIN ANTIBODY GD3G7
J. Biol. Chem.,
July 6, 2007;
282(27):
19442 - 19452.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S Deepa, S. Yamada, S. Fukui, and K. Sugahara
Structural determination of novel sulfated octasaccharides isolated from chondroitin sulfate of shark cartilage and their application for characterizing monoclonal antibody epitopes
Glycobiology,
June 1, 2007;
17(6):
631 - 645.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Li, A. K. Shetty, and K. Sugahara
Neuritogenic Activity of Chondroitin/Dermatan Sulfate Hybrid Chains of Embryonic Pig Brain and Their Mimicry from Shark Liver: INVOLVEMENT OF THE PLEIOTROPHIN AND HEPATOCYTE GROWTH FACTOR SIGNALING PATHWAYS
J. Biol. Chem.,
February 2, 2007;
282(5):
2956 - 2966.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Mitsunaga, T. Mikami, S. Mizumoto, J. Fukuda, and K. Sugahara
Chondroitin Sulfate/Dermatan Sulfate Hybrid Chains in the Development of Cerebellum: SPATIOTEMPORAL REGULATION OF THE EXPRESSION OF CRITICAL DISULFATED DISACCHARIDES BY SPECIFIC SULFOTRANSFERASES
J. Biol. Chem.,
July 14, 2006;
281(28):
18942 - 18952.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Deepa, D. Carulli, C. Galtrey, K. Rhodes, J. Fukuda, T. Mikami, K. Sugahara, and J. W. Fawcett
Composition of Perineuronal Net Extracellular Matrix in Rat Brain: A DIFFERENT DISACCHARIDE COMPOSITION FOR THE NET-ASSOCIATED PROTEOGLYCANS
J. Biol. Chem.,
June 30, 2006;
281(26):
17789 - 17800.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. C. Miller, C. E. Costello, A. Malmstrom, and J. Zaia
A tandem mass spectrometric approach to determination of chondroitin/dermatan sulfate oligosaccharide glycoforms
Glycobiology,
June 1, 2006;
16(6):
502 - 513.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Maccarana, B. Olander, J. Malmstrom, K. Tiedemann, R. Aebersold, U. Lindahl, J.-p. Li, and A. Malmstrom
Biosynthesis of Dermatan Sulfate: CHONDROITIN-GLUCURONATE C5-EPIMERASE IS IDENTICAL TO SART2
J. Biol. Chem.,
April 28, 2006;
281(17):
11560 - 11568.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. von Holst, S. Sirko, and A. Faissner
The Unique 473HD-Chondroitinsulfate Epitope Is Expressed by Radial Glia and Involved in Neural Precursor Cell Proliferation
J. Neurosci.,
April 12, 2006;
26(15):
4082 - 4094.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Liu, C.-H. Chau, H. Liu, B. R. Jang, X. Li, Y.-S. Chan, and D. K. Y. Shum
Upregulation of chondroitin 6-sulphotransferase-1 facilitates Schwann cell migration during axonal growth.
J. Cell Sci.,
March 1, 2006;
119(Pt 5):
933 - 942.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Ohtake, K. Kimata, and O. Habuchi
Recognition of Sulfation Pattern of Chondroitin Sulfate by Uronosyl 2-O-Sulfotransferase
J. Biol. Chem.,
November 25, 2005;
280(47):
39115 - 39123.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Bao, T. Muramatsu, and K. Sugahara
Demonstration of the Pleiotrophin-binding Oligosaccharide Sequences Isolated from Chondroitin Sulfate/Dermatan Sulfate Hybrid Chains of Embryonic Pig Brains
J. Biol. Chem.,
October 21, 2005;
280(42):
35318 - 35328.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Bao, M. S. G. Pavao, J. C. dos Santos, and K. Sugahara
A Functional Dermatan Sulfate Epitope Containing Iduronate(2-O-sulfate){alpha}1-3GalNAc(6-O-sulfate) Disaccharide in the Mouse Brain: DEMONSTRATION USING A NOVEL MONOCLONAL ANTIBODY RAISED AGAINST DERMATAN SULFATE OF ASCIDIAN ASCIDIA NIGRA
J. Biol. Chem.,
June 17, 2005;
280(24):
23184 - 23193.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Ito, M. Hikino, Y. Yajima, T. Mikami, S. Sirko, A. von Holst, A. Faissner, S. Fukui, and K. Sugahara
Structural characterization of the epitopes of the monoclonal antibodies 473HD, CS-56, and MO-225 specific for chondroitin sulfate D-type using the oligosaccharide library
Glycobiology,
June 1, 2005;
15(6):
593 - 603.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Bao, T. Mikami, S. Yamada, A. Faissner, T. Muramatsu, and K. Sugahara
Heparin-binding Growth Factor, Pleiotrophin, Mediates Neuritogenic Activity of Embryonic Pig Brain-derived Chondroitin Sulfate/Dermatan Sulfate Hybrid Chains
J. Biol. Chem.,
March 11, 2005;
280(10):
9180 - 9191.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. D. Nandini, N. Itoh, and K. Sugahara
Novel 70-kDa Chondroitin Sulfate/Dermatan Sulfate Hybrid Chains with a Unique Heterogenous Sulfation Pattern from Shark Skin, Which Exhibit Neuritogenic Activity and Binding Activities for Growth Factors and Neurotrophic Factors
J. Biol. Chem.,
February 11, 2005;
280(6):
4058 - 4069.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. D. Nandini, T. Mikami, M. Ohta, N. Itoh, F. Akiyama-Nambu, and K. Sugahara
Structural and Functional Characterization of Oversulfated Chondroitin Sulfate/Dermatan Sulfate Hybrid Chains from the Notochord of Hagfish: NEURITOGENIC AND BINDING ACTIVITIES FOR GROWTH FACTORS AND NEUROTROPHIC FACTORS
J. Biol. Chem.,
December 3, 2004;
279(49):
50799 - 50809.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Bao, S. Nishimura, T. Mikami, S. Yamada, N. Itoh, and K. Sugahara
Chondroitin Sulfate/Dermatan Sulfate Hybrid Chains from Embryonic Pig Brain, Which Contain a Higher Proportion of L-Iduronic Acid than Those from Adult Pig Brain, Exhibit Neuritogenic and Growth Factor Binding Activities
J. Biol. Chem.,
March 12, 2004;
279(11):
9765 - 9776.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Hikino, T. Mikami, A. Faissner, A.-C. E. S. Vilela-Silva, M. S. G. Pavao, and K. Sugahara
Oversulfated Dermatan Sulfate Exhibits Neurite Outgrowth-promoting Activity toward Embryonic Mouse Hippocampal Neurons: IMPLICATIONS OF DERMATAN SULFATE IN NEURITOGENESIS IN THE BRAIN
J. Biol. Chem.,
October 31, 2003;
278(44):
43744 - 43754.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Maeda, J. He, Y. Yajima, T. Mikami, K. Sugahara, and T. Yabe
Heterogeneity of the Chondroitin Sulfate Portion of Phosphacan/6B4 Proteoglycan Regulates Its Binding Affinity for Pleiotrophin/Heparin Binding Growth-associated Molecule
J. Biol. Chem.,
September 12, 2003;
278(37):
35805 - 35811.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Garwood, N. Heck, F. Reichardt, and A. Faissner
Phosphacan Short Isoform, a Novel Non-proteoglycan Variant of Phosphacan/Receptor Protein Tyrosine Phosphatase-{beta}, Interacts with Neuronal Receptors and Promotes Neurite Outgrowth
J. Biol. Chem.,
June 20, 2003;
278(26):
24164 - 24173.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Deepa, Y. Umehara, S. Higashiyama, N. Itoh, and K. Sugahara
Specific Molecular Interactions of Oversulfated Chondroitin Sulfate E with Various Heparin-binding Growth Factors. IMPLICATIONS AS A PHYSIOLOGICAL BINDING PARTNER IN THE BRAIN AND OTHER TISSUES
J. Biol. Chem.,
November 8, 2002;
277(46):
43707 - 43716.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-P. Zanetta, R. Bindeus, G. Normand, V. Durier, P. Lagant, E. Maes, and G. Vergoten
Evidence for a Lectin Activity for Human Interleukin 3 and Modeling of Its Carbohydrate Recognition Domain
J. Biol. Chem.,
October 4, 2002;
277(41):
38764 - 38771.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. G. Becker and T. Becker
Repellent Guidance of Regenerating Optic Axons by Chondroitin Sulfate Glycosaminoglycans in Zebrafish
J. Neurosci.,
February 1, 2002;
22(3):
842 - 853.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Harroch, M. Palmeri, J. Rosenbluth, A. Custer, M. Okigaki, P. Shrager, M. Blum, J. D. Buxbaum, and J. Schlessinger
No Obvious Abnormality in Mice Deficient in Receptor Protein Tyrosine Phosphatase beta
Mol. Cell. Biol.,
October 15, 2000;
20(20):
7706 - 7715.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
J. Garwood, O. Schnadelbach, A. Clement, K. Schutte, A. Bach, and A. Faissner
DSD-1-Proteoglycan Is the Mouse Homolog of Phosphacan and Displays Opposing Effects on Neurite Outgrowth Dependent on Neuronal Lineage
J. Neurosci.,
May 15, 1999;
19(10):
3888 - 3899.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Ueoka, N. Kaneda, I. Okazaki, S. Nadanaka, T. Muramatsu, and K. Sugahara
Neuronal Cell Adhesion, Mediated by the Heparin-binding Neuroregulatory Factor Midkine, Is Specifically Inhibited by Chondroitin Sulfate E. STRUCTURAL AND FUNCTIONAL IMPLICATIONS OF THE OVER-SULFATED CHONDROITIN SULFATE
J. Biol. Chem.,
November 22, 2000;
275(48):
37407 - 37413.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Uchimura, K. Kadomatsu, H. Nishimura, H. Muramatsu, E. Nakamura, N. Kurosawa, O. Habuchi, F. M. El-Fasakhany, Y. Yoshikai, and T. Muramatsu
Functional Analysis of the Chondroitin 6-Sulfotransferase Gene in Relation to Lymphocyte Subpopulations, Brain Development, and Oversulfated Chondroitin Sulfates
J. Biol. Chem.,
January 4, 2002;
277(2):
1443 - 1450.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Tsuchida, J. Shioi, S. Yamada, G. Boghosian, A. Wu, H. Cai, K. Sugahara, and N. K. Robakis
Appican, the Proteoglycan Form of the Amyloid Precursor Protein, Contains Chondroitin Sulfate E in the Repeating Disaccharide Region and 4-O-Sulfated Galactose in the Linkage Region
J. Biol. Chem.,
September 28, 2001;
276(40):
37155 - 37160.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|